Mode
Text Size
Log in / Sign up
N/A Completed N=218

POLARSTEM Cementless Hip Stem

Source: ClinicalTrials.gov NCT02648152 ↗
Enrolled (actual)
218
Serious AEs
52.3%
Results posted
Jan 2026
Primary outcomePrimary: Kaplan-Meier Estimate: Overall Survivorship of POLARSTEM — 100; 99.6; 99.1; 98.7 percentage of hips

Summary

Multicenter observational study to validate that the POLARSTEM™ is a state-of-the-art implant in terms of radiographic, clinical performance and long-term survivorship.

Outcome Measures

OutcomeResultp-value
PRIMARY
Kaplan-Meier Estimate: Overall Survivorship of POLARSTEM
100; 99.6; 99.1; 98.7; 98.7; 98.7
SECONDARY
Harris Hip Score (HHS)
48.60; 83.10; 89.20; 89.10; 88.00; 85.30
SECONDARY
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): Pain Subscale
11.5; 1.9; 1.5; 1.7; 1.5; 1.0
SECONDARY
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): Stiffness Subscale
5.0; 1.6; 1.1; 1.0; 0.7; 0.6
SECONDARY
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): Physical Function Subscale
42.1; 10.8; 8.0; 8.0; 9.3; 5.9
SECONDARY
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): Total Score
58.6; 14.2; 10.5; 10.7; 11.6; 7.4
SECONDARY
Radiological: Radiolucent Lines
2; 217; 0; 215; 7; 183
SECONDARY
Radiological: Osteolysis
0; 219; 1; 214; 1; 189
SECONDARY
Radiological: Atrophy
1; 0; 0; 0; 218; 0
SECONDARY
Radiological: Hypertrophy
0; 0; 0; 0; 219; 0
SECONDARY
Radiological: Loosening of the Implant or Migration
4; 138; 77; 0; 0; 0

Eligibility Criteria

Inclusion Criteria

  • Patient has no general medical contraindication to surgery
  • Informed consent to participate in the MCO signed by the patient
  • Routine radiographic assessment is possible
  • Patient is likely to comply with study follow-up requirements
  • Primary total hip replacement (THR) to the affected side, unilateral or bilateral

Exclusion Criteria

  • Previously failed endoprosthesis and /or THR components in relevant hip
  • History of infection in the affected joint; systemic infections
  • Grossly insufficient femoral or acetabular bone stock in the involved hip
  • Charcot joint disease or other severe neurosensory deficit
  • Severe spinal disorders
  • Age of patient at date of surgery > 75 years
  • High comorbidity
  • Cemented acetabular cup
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02648152). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search